2 active not recruiting, 1 recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 2, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Synthekine: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease SYNCAR-001, STK-009 - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 | Active not recruiting | Synthekine | 48 | 2025-04-29 | 2026-07-10 |
| Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies SYNCAR-001, STK-009, Cyclophosphamide - CLL/SLL, NHL | Phase 1 | Active not recruiting | Synthekine | 36 | 2023-04-23 | 2026-07-10 |
| Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers STK-012, pembrolizumab KEYTRUDA®, pemetrexed - Advanced Solid Tumor, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Synthekine | 364 | 2022-01-25 | 2026-10-29 |
Carcinoma, Non-Small-Cell Lung (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Scleroderma, Systemic (1)
Carboplatin (1) · Cyclophosphamide (1) · Pemetrexed (1) · fludarabine (1) · pembrolizumab (1)
United States (3) · Georgia (1) · Ireland (1) · Italy (1) · Poland (1) · Spain (1)
2025 (1)